Abstract:Objective To study the clinical features and gene mutations of early-onset epileptic encephalopathy (EOEE) and to explore the application in pathogenic diagnosis of EOEE by next generation sequencing. Methods The clinical data of 68 cases diagnosed with unexplained EOEE between June 2014 and December 2017 were obtained and analyzed. Specimens were collected from the selected children and their parents. Next generation sequencing was used to detect epilepsy ? related genes, and Sanger sequencing was performed to verify the results and confirm the source of parents, further to identify suspected pathogenic mutations of EOEE. Results Among 68 cases with EOEE, 18 cases (26.47%) were detected with epilepsy?related genes. One was diagnosed as pyridoxine dependent epilepsy (PDE), which was caused by ALDH7A1 mutation. One was diagnosed as thiamine metabolism dysfunction syndrome 2 (THMD2), which was caused by SLC19A3 mutation. Among 13 cases of epilepsy syndrome, 6 cases were diagnosed as Dravet's syndrome (DS), 5 caused by SCN1A missense mutation and one by SCN1A nonsense mutation; 4 cases were diagnosed as infantile spasm (IS), one caused by TSC1 nonsense mutation but the pathogenicity can not be identified while pathogenic mutations were not detected in other 3 cases; 2 cases were diagnosed as Ohtahara's syndrome (OS), one caused by STXBP1 missense mutation and pathogenic mutation was not found in the other; one case of malignant migrating partial seizures in infancy (MMPEI) was not found the pathogenic mutations. Among 53 cases with non-specific EOEE, suspected pathogenic mutations were detected in 9 cases: one case of CN8A missense mutation, one case of KCNQ2 missense mutation, one case of KCNH5 missense mutation, one case of CACNA1A missense mutation, 2 cases of CDKL5 nonsense mutation, one case of CDKL5 frame-shift mutation, one case of PCDH19 nonsense mutation and one case of GRIN2A missense mutation. All cases were treated by 2 and more antiepileptic drugs (AEDs), one case of PDE was given vitamin B6 20 mg/(kg·d), and one case of THMD2 was given vitamin B1 25 mg/(kg·d) and biotin 2 mg/(kg·d). After followed by 6 months to 8 years, 15 cases (22.06%) were seizure free, 21 cases (30.88% ) were part of control and 32 cases (47.06% ) were out of control. Conclusions The clinical phenotypes of children with unexplained EOEE are varied. One case was diagnosed as PDE and one as THMD2 after gene sequencing. After treated by etiological treatment, patients with remediable genetic disease were seizure free. Some gene sites were denovo mutations which have not been reported such as missense mutation for SCN1A, STXBP1, KCNH5, CACNA1A, frame-shift mutation for CDKL5, and onsense mutation for PCDH19, which enriched the mutation spectrum of EOEE. DOI: 10.3969/j.issn.1672-6731.2018.06.008

Genetic Diagnosis in Children with Epilepsy and Developmental Disorders by Targeted Gene Panel Analysis in a Developing Country

Importance of targeted next-generation sequencing in pediatric patients with developmental epileptic encephalopathy

Diagnostic yield of genetic testing in epileptic encephalopathy in childhood

Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy

Gene Mutation Analysis In 253 Chinese Children With Unexplained Epilepsy And Intellectual/Developmental Disabilities

Investigation of patients with childhood epilepsy in single center: Comprehensive genetic testing experience

Genetic Testing in Children with Developmental and Epileptic Encephalopathies: A Review of Advances in Epilepsy Genomics

Clinical Application of Targeted Next-Generation Sequencing Panels and Whole Exome Sequencing in Childhood Epilepsy

Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies.

Clinical Phenotype, Gene Mutation and Application of Targeted Next Generation Sequencing in Patients with Early-Onset Epileptic Encephalopathy

High Diagnostic Yield and Clinical Utility of Next-Generation Sequencing in Children with Epilepsy and Neurodevelopmental Delays: A Retrospective Study

A retrospective study of the yield of next‐generation sequencing in the diagnosis of developmental and epileptic encephalopathies and epileptic encephalopathies in 0–12 years aged children at a single tertiary care hospital in South India

Customized targeted massively parallel sequencing enables the identification of novel pathogenic variants in Tunisian patients with developmental and epileptic encephalopathy

Clinical and Genetic Spectrum of a Large Cohort of Children with Epilepsy in China

Next Generation Sequencing in Children with Unexplained Epilepsy: A Retrospective Cohort Study.

Next-generation sequencing in pediatric-onset epilepsies: Analysis with target panels and personalized therapeutic approach

Common genes and recurrent causative variants in 957 Asian patients with pediatric epilepsy

Developmental and Epileptic Encephalopathies: Need for Bridging the Gaps Between Clinical Syndromes and Underlying Genetic Etiologies

Clinical Features and Gene Mutations Analysis in 62 Children with Early - Onset Epileptic Encephalopathy of Un-Known Causes

Next-generation sequencing testing in children with epilepsy reveals novel clinical, diagnostic and therapeutic implications

Genetic diagnoses in pediatric patients with epilepsy and comorbid intellectual disability.